Clinical Trials Browser

INDUSTRY × Carcinoid Tumor × NET × Clear all

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02270567 2025-11-13

RegisterNET

Enrolling by invitation

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Disease Progression

NCT05361668 2025-10-31

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2 Active not recruiting

36 enrolled 19 charts

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07165132 2025-09-10

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 Not yet recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Phase 3 Completed

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Phase 2 Completed

43 enrolled 12 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00688623 2019-01-25

RAMSETE/CDE16

Phase 2 Completed

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Phase 2 Completed

18 enrolled 10 charts

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 2 Completed

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

NCT00339131 2011-10-12

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Phase 1 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00780663 2011-06-15

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 2 Completed

Carcinoid Tumor, Neuroendocrine Tumors